Levetiracetam
13 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
13
Ongoing
3
Recruiting
3
Completed
7
Sites
40
Countries
5
Endpoints
145
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 145 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 37 of 145 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
10
9
7
4
4
2
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
13 of 13
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| HOPE4MCIStudy of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease | Levetiracetam Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 2/3 | Completed | 24 | Nov 2022 | - | results |
| LESS-ADLEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome | Levetiracetam Alzheimer’s disease | Age ≥40 | Ph 3 | Recruiting | 5 | Dec 2027 | - | |
| ALEVIATE-2Levetiracetam for Persons at Risk for Alzheimer's Disease | Levetiracetam Alzheimer’s disease | Family history of Alzheimer’s disease required | Ph 2 | Recruiting | 2 | Jan 2027 | - | |
| LEV-ADLevetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability | Levetiracetam Alzheimer’s disease | Alzheimer's disease | Ph 2 | Completed | 2 | Jul 2020 | 16 | results |
| NCT05969054Improvement Effect of Lacosamide and Levetiracetam on Cognitive in Alzheimer's Disease Patients With Epilepsy | Lacosamide, Levetiracetam Alzheimer’s disease | MMSE ≥18 | Ph 4 | Unknown | 1 | Dec 2025 | - | |
| NCT01044758Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) | Levetiracetam MCI / preclinical Alzheimer’s | Age 50-85 | Ph 2 | Completed | 1 | Jul 2012 | 7 | results |
| NCT05986721Clinical Trial of AGB101 for Mild Cognitive Impairment | Levetiracetam Alzheimer’s disease, MCI / preclinical Alzheimer’s | MCI due to AD | Ph 2 | Withdrawn | 1 | Jul 2028 | - | |
| ILiADAn Investigation of Levetiracetam in Alzheimer's Disease | Levetiracetam Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 1 | Mar 2022 | 2 | |
| NCT01318408Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia | Levetiracetam Alzheimer’s disease, MCI / preclinical Alzheimer’s, Mixed / unspecified dementia | Multiple dementia etiologies | Ph 4 | Completed | 1 | Mar 2008 | 1 | results |
| LeADTreating Hyperexcitability in AD With Levetiracetam | Levetiracetam Alzheimer’s disease, MCI / preclinical Alzheimer’s | Alzheimer's disease | Ph 2 | Completed | 1 | Feb 2026 | 2 | |
| AGB101-CNClinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults | Levetiracetam Mixed / unspecified dementia | MMSE 27-30 | Ph 2 | Recruiting | 1 | May 2027 | 5 | |
| NCT03461861Network-Level Mechanisms for Preclinical Alzheimer's Disease Development | Levetiracetam Alzheimer’s disease | MoCA 23 | Ph 2 | Completed | 1 | Mar 2021 | 15 | results |
| LAPSELevetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) | Levetiracetam Alzheimer’s disease | Alzheimer's disease | Ph 2 | Unknown | 1 | Dec 2024 | 45 |
Showing 1-13 of 13 trials